Matthew Majewski

Vice President

Mr. Matthew Majewski has a track record of providing life science clients with analytically based solutions to their strategic issues.

He has led a wide range of corporate and asset-specific strategy engagements, many of which have focused on pricing and market access. Mr. Majewski has deep experience in the specialty disease space and has provided insights to many clients with rare disease, oncology, and cell & gene therapy assets across the retail, specialty, and hospital channels. Prior to joining CRA, Mr. Majewski was a consultant at a biopharmaceutical organization where he developed and managed market strategies for pre-launch products and designed and managed market organizations.

Selected engagements

  • 01
    Establishing real-world testing and treatment patterns for EGFR NSCLC patients
    Oncology-focused biotech was looking to establish real-world testing and treatment patterns among EGFR NSCLC patients in US, EU, Japan, and Greater China...
    View engagement
  • 02
    Modeling the financial implications of innovative gene therapy business models
    Biotech client was looking to evaluate the financial implications of various innovative business models/strategic offerings for its novel gene therapy.
    View engagement
  • 03
    Long-term strategic partner in bladder cancer
    We formed a long-term, multi-project partnership with a leading manufacturer that was looking to establish its new product as standard of care in bladder...
    View engagement